{
    "2018-11-27": [
        [
            {
                "time": "2018-03-15",
                "original_text": "Roche buys U.S. biotech Jecure in race for liver disease drugs",
                "features": {
                    "keywords": [
                        "Roche",
                        "buys",
                        "U.S.",
                        "biotech",
                        "Jecure",
                        "liver disease",
                        "drugs"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-04-20",
                "original_text": "Novartis's Alcon sees myopia epidemic driving sales growth",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Alcon",
                        "myopia",
                        "epidemic",
                        "sales",
                        "growth"
                    ],
                    "sentiment_score": 0.65,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "ophthalmology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-05-10",
                "original_text": "3 Reasons Why Glaxo (GSK) Stock is Up This Year So Far",
                "features": {
                    "keywords": [
                        "Glaxo",
                        "GSK",
                        "Stock",
                        "Up",
                        "Year"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-06-05",
                "original_text": "Alcon To Highlight Vision, Strategy, Benefits As Standalone Company Post Spinoff",
                "features": {
                    "keywords": [
                        "Alcon",
                        "Vision",
                        "Strategy",
                        "Benefits",
                        "Standalone",
                        "Company",
                        "Spinoff"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "ophthalmology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}